{"id":"mibolerone","rwe":[{"pmid":"38529542","year":"2024","title":"The antiviral potential of the antiandrogen enzalutamide and the viral-androgen signaling interplay in seasonal coronaviruses.","finding":"","journal":"Journal of medical virology","studyType":"Clinical Study"},{"pmid":"29917167","year":"2018","title":"Androgen receptor induces EPHA3 expression by interacting with transcription factor SP1.","finding":"","journal":"Oncology reports","studyType":"Clinical Study"},{"pmid":"28234904","year":"2017","title":"Biotransformation of a potent anabolic steroid, mibolerone, with Cunninghamella blakesleeana, C. echinulata, and Macrophomina phaseolina, and biological activity evaluation of its metabolites.","finding":"","journal":"PloS one","studyType":"Clinical Study"},{"pmid":"27399684","year":"2016","title":"Anti-Cancer Effect of Lambertianic Acid by Inhibiting the AR in LNCaP Cells.","finding":"","journal":"International journal of molecular sciences","studyType":"Clinical Study"},{"pmid":"25956809","year":"2015","title":"Axon diameter and axonal transport: In vivo and in vitro effects of androgens.","finding":"","journal":"NeuroImage","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Androgen receptor","category":"target"},{"label":"AR","category":"gene"},{"label":"Active","category":"status"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["mibolerone","U-10997","NSC-72260"],"offLabel":[],"synonyms":["mibolerone","U-10997","NSC-72260"],"timeline":[],"aiSummary":"Mibolerone is a small molecule that targets the androgen receptor, a protein involved in the development and maintenance of male characteristics. It is not FDA-approved for any indications, and its commercial status is unknown. Mibolerone works by binding to the androgen receptor, which can lead to changes in gene expression and cellular function. As a result, it may be used to treat conditions related to androgen excess or deficiency. However, due to its unknown commercial status and lack of FDA approval, its use is not well-established.","approvals":[{"date":"","orphan":false,"company":"","regulator":"FDA"}],"ecosystem":[],"mechanism":{"target":"Androgen receptor, Androgen receptor","novelty":"First-in-class","targets":[{"gene":"AR","source":"DrugCentral","target":"Androgen receptor","protein":"Androgen receptor"}],"modality":"Small Molecule","explanation":"Think of the androgen receptor like a key that unlocks certain genes in your body. When mibolerone binds to this receptor, it's like giving the key to the wrong person - it can cause changes in how your body functions, particularly in terms of male characteristics. This can be useful for treating conditions related to androgen excess or deficiency.","oneSentence":"Mibolerone works by binding to the androgen receptor, mimicking the effects of male hormones.","technicalDetail":"Mibolerone acts as a selective androgen receptor modulator (SARM), binding to the androgen receptor with high affinity and specificity, leading to agonist activity and subsequent changes in gene expression and cellular function."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5578","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=MIBOLERONE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MIBOLERONE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T14:31:26.913929","biosimilars":[],"competitors":[{"drugName":"abiraterone acetate","drugSlug":"abiraterone-acetate","fdaApproval":"2011-04-28","patentExpiry":"May 20, 2034","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"apalutamide","drugSlug":"apalutamide","fdaApproval":"2018-02-14","patentExpiry":"Sep 23, 2033","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"bicalutamide","drugSlug":"bicalutamide","fdaApproval":"1995-10-04","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"clascoterone","drugSlug":"clascoterone","fdaApproval":"2020-08-26","patentExpiry":"Nov 20, 2028","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"danazol","drugSlug":"danazol","fdaApproval":"1976-06-21","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"darolutamide","drugSlug":"darolutamide","fdaApproval":"2019-07-30","patentExpiry":"Oct 27, 2030","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"dexamethasone","drugSlug":"dexamethasone","fdaApproval":"1958-10-30","patentExpiry":"Oct 7, 2036","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"dexamethasone phosphate","drugSlug":"dexamethasone-phosphate","fdaApproval":"1959-09-02","relationship":"same-target"},{"drugName":"dorzolamide","drugSlug":"dorzolamide","fdaApproval":"1994-12-09","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"drospirenone","drugSlug":"drospirenone","fdaApproval":"2019-05-23","patentExpiry":"Jun 28, 2031","patentStatus":"Patent protected","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"mibolerone","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"abiraterone-acetate","brandName":"abiraterone acetate","genericName":"abiraterone acetate","approvalYear":"2011","relationship":"same-target"},{"drugId":"apalutamide","brandName":"apalutamide","genericName":"apalutamide","approvalYear":"2018","relationship":"same-target"},{"drugId":"bicalutamide","brandName":"bicalutamide","genericName":"bicalutamide","approvalYear":"1995","relationship":"same-target"},{"drugId":"clascoterone","brandName":"clascoterone","genericName":"clascoterone","approvalYear":"2020","relationship":"same-target"},{"drugId":"danazol","brandName":"danazol","genericName":"danazol","approvalYear":"1976","relationship":"same-target"},{"drugId":"darolutamide","brandName":"darolutamide","genericName":"darolutamide","approvalYear":"2019","relationship":"same-target"},{"drugId":"dexamethasone","brandName":"dexamethasone","genericName":"dexamethasone","approvalYear":"1958","relationship":"same-target"},{"drugId":"dexamethasone-phosphate","brandName":"dexamethasone phosphate","genericName":"dexamethasone phosphate","approvalYear":"1959","relationship":"same-target"},{"drugId":"dorzolamide","brandName":"dorzolamide","genericName":"dorzolamide","approvalYear":"1994","relationship":"same-target"},{"drugId":"drospirenone","brandName":"drospirenone","genericName":"drospirenone","approvalYear":"2019","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT06059521","phase":"NA","title":"Software Refraction With Mobilerone Versus Retinoscopy","status":"RECRUITING","sponsor":"Beijing Airdoc Technology Co., Ltd.","startDate":"2023-07-15","conditions":["Myopia","Myopia, Moderate","Astigmatism"],"enrollment":120,"completionDate":"2030-12-30"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"MMSL":"NOCODE","UNII":"9OGY4BOR8D","CHEBI":"CHEBI:34849","INN_ID":"3203","UMLSCUI":"C0066502","ChEMBL_ID":"CHEMBL425863","KEGG_DRUG":"D05025","DRUGBANK_ID":"DB11429","PUBCHEM_CID":"251636","SNOMEDCT_US":"96342004","IUPHAR_LIGAND_ID":"2859","SECONDARY_CAS_RN":"3704-09-4","MESH_SUPPLEMENTAL_RECORD_UI":"C100075"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":196,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"2024 Mar","pmid":"38529542","title":"The antiviral potential of the antiandrogen enzalutamide and the viral-androgen signaling interplay in seasonal coronaviruses.","journal":"Journal of medical virology"},{"date":"2018 Aug","pmid":"29917167","title":"Androgen receptor induces EPHA3 expression by interacting with transcription factor SP1.","journal":"Oncology reports"},{"date":"2017","pmid":"28234904","title":"Biotransformation of a potent anabolic steroid, mibolerone, with Cunninghamella blakesleeana, C. echinulata, and Macrophomina phaseolina, and biological activity evaluation of its metabolites.","journal":"PloS one"},{"date":"2016 Jul 7","pmid":"27399684","title":"Anti-Cancer Effect of Lambertianic Acid by Inhibiting the AR in LNCaP Cells.","journal":"International journal of molecular sciences"},{"date":"2015 Jul 15","pmid":"25956809","title":"Axon diameter and axonal transport: In vivo and in vitro effects of androgens.","journal":"NeuroImage"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"MIBOLERONE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}